Comparison of adverse events during capecitabine versus 5-fluorouracil/oxaliplatin adjuvantchemotherapy for stage II/III colon cancer: A population based analysis.

被引：0
|
作者：
Pabani, Aliyah
Mazurek, Matthew
Cheung, Winson Y.
Spratlin, Jennifer L.
Hiller, Julie A. Price
Standeven, Leah Jean
Mulder, Karen E.
Ghosh, Sunita
Ho, Maria Yi
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14663
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)
    Chakravarthy, A. Bapsi
    Zhao, Fengmin
    Meropol, Neal J.
    Flynn, Patrick J.
    Wagner, Lynne, I
    Sloan, Jeffrey
    Diasio, Robert B.
    Mitchell, Edith P.
    Catalano, Paul
    Giantonio, Bruce J.
    Catalano, Robert B.
    Haller, Daniel G.
    Awan, Rashid A.
    Mulcahy, Mary F.
    O'Brien, Timothy E.
    Santala, Roger
    Cripps, Christine
    Weis, John R.
    Atkins, James N.
    Leichman, Cynthia G.
    Petrelli, Nicholas J.
    Sinicrope, Frank A.
    Brierley, James D.
    Tepper, Joel E.
    O'Dwyer, Peter J.
    Sigurdson, Elin R.
    Hamilton, Stanley R.
    Cella, David
    Benson, Al B., III
    ONCOLOGIST, 2020, 25 (05): : E798 - E807
  • [42] Selecting patients with stage II/III colorectal cancer for 5-fluorouracil-based adjuvant chemotherapy using proteomic analysis.
    Yan, Dongyao
    Hong, Ji Hyung
    Lee, Hee Yeon
    Byun, Jae Ho
    Cecchi, Fabiola
    Tian, Yuan
    Schwartz, Sarit
    An, Eunkyung
    Hembrough, Todd A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [43] Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)
    Nakayama, Goro
    Takano, Nao
    Taniguchi, Hiroya
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Teramoto, Hitoshi
    Hashimoto, Ryoji
    Sakai, Mitsuru
    Ishiyama, Akiharu
    Kinoshita, Takashi
    Hayashi, Naomi
    Nakamura, Masanori
    Hattori, Norifumi
    Sato, Yusuke
    Umeda, Shinichi
    Uehara, Kei
    Aiba, Toshisada
    Sonohara, Fuminori
    Hayashi, Masamichi
    Kanda, Mitsuro
    Kobayashi, Daisuke
    Tanaka, Chie
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Murotani, Kenta
    Ando, Masahiko
    Ando, Yuichi
    Muro, Kei
    Kodera, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 61 - 71
  • [44] A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
    Jinno, H.
    Sakata, M.
    Hayashida, T.
    Takahashi, M.
    Mukai, M.
    Ikeda, T.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2010, 21 (06) : 1262 - 1266
  • [45] Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study
    Lee, Kil-yong
    Park, Ji Won
    Lee, Ki-young
    Cho, Sangsik
    Kwon, Yoon-Hye
    Kim, Min Jung
    Ryoo, Seung-Bum
    Jeong, Seung-Yong
    Park, Kyu Joo
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2019, 34 (04) : 629 - 639
  • [46] Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study
    Kil-yong Lee
    Ji Won Park
    Ki-young Lee
    Sangsik Cho
    Yoon-Hye Kwon
    Min Jung Kim
    Seung-Bum Ryoo
    Seung-Yong Jeong
    Kyu Joo Park
    International Journal of Colorectal Disease, 2019, 34 : 629 - 639
  • [47] Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer
    Dietmaier, W
    Bettstetter, M
    Wild, PJ
    Woenckhaus, M
    Rümmele, P
    Hartmann, A
    Dechant, S
    Blaszyk, H
    Pauer, A
    Klinkhammer-Schalke, M
    Hofstädter, F
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (09) : 2247 - 2254
  • [48] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
    Pectasides, Dimitrios
    Karavasilis, Vasilios
    Papaxoinis, George
    Gourgioti, Georgia
    Makatsoris, Thomas
    Raptou, Georgia
    Vrettou, Eleni
    Sgouros, Joseph
    Samantas, Epaminontas
    Basdanis, George
    Papakostas, Pavlos
    Bafaloukos, Dimitrios
    Kotoula, Vassiliki
    Kalofonos, Haralambos P.
    Scopa, Chrisoula D.
    Pentheroudakis, George
    Fountzilas, George
    BMC CANCER, 2015, 15
  • [49] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
    Dimitrios Pectasides
    Vasilios Karavasilis
    George Papaxoinis
    Georgia Gourgioti
    Thomas Makatsoris
    Georgia Raptou
    Eleni Vrettou
    Joseph Sgouros
    Epaminontas Samantas
    George Basdanis
    Pavlos Papakostas
    Dimitrios Bafaloukos
    Vassiliki Kotoula
    Haralambos P. Kalofonos
    Chrisoula D. Scopa
    George Pentheroudakis
    George Fountzilas
    BMC Cancer, 15
  • [50] Toxicity of Oxaliplatin Plus Fluorouracil/Leucovorin Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer: A Population-Based Study
    Hamza, Samia
    Bouvier, Anne-Marie
    Rollot, Fabien
    Lepage, Come
    Faivre, Jean
    Bedenne, Laurent
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (08) : 2636 - 2641
12345